CLAIM AMENDMENTS

1. (Currently Amended) A method for the formulation and delivery of an acid-labile pharmaceutical compound selected from the group consisting of substituted benzimidazoles and pancreatic enzyme supplements, said method comprising:

a. providing an active pharmaceutical compound;

b. providing a basic salt as one of a powder, a suspension and a solution having a pH greater than 7;

c. combining said active pharmaceutical compound in a form as one of a tablet, a capsule, and a powder with said basic salt as one of the powder, the solution and the suspension to convert said acid-labile pharmaceutical compound into a non-enteric coated tablet, capsule or liquid formulation; ~~and~~

d. delivering the non-enteric coated liquid formulation of said acid-labile pharmaceutical compound to patients who

are unable to swallow intact capsules or tablets orally by an artificial feeding tube inserted in the patients' gastrointestinal tract; and

e. said basic salt being one of magnesium, calcium and aluminum.

2-5. (Canceled)

5. (Previously Amended) A method for the formulation and delivery of an acid-labile pharmaceutical compound as claimed in Claim 1, wherein said compound in said formulation includes a therapeutic dose of said active pharmaceutical compound.

6. (Canceled)

7. (Currently Amended) An acid-labile pharmaceutical compound having at least substituted benzimidazoles and pancreatic enzyme supplements, said acid-labile pharmaceutical compound comprising:

a. an active pharmaceutical compound;

b. a basic salt, which basic salt is at least one of a powder, a solution and a suspension;

c. said one of said powder, said solution and said suspension having a pH greater than 7.0;

d. said active pharmaceutical compound and said basic salt combined as at least one of a form of a tablet, capsule, and powder;

e. said at least one of a form of a tablet, capsule and powder provided to said one of said solution and said suspension to convert said acid-labile pharmaceutical compound into a non-enteric coated tablet, capsule, or liquid formulation which is operable to provide at least one of neutralization of gastric acid and temporary stimulation of gastric acid secretion; ~~and~~

f. the non-enteric coated liquid formulation of said acid-labile pharmaceutical compound being delivered to patients who are unable to swallow intact capsules or tablets orally by an artificial feeding tube inserted in the patients' gastrointestinal tract; and

g. said basic salt being one of magnesium, calcium and aluminum.

8-9(Canceled)

10. (Original) An acid-labile pharmaceutical compound as claimed in Claim 7, wherein said pharmaceutical compound in said at least one form has at least a therapeutic dose of said pharmaceutical compound.

11. (Original) An acid-labile pharmaceutical compound as claimed in Claim 10, wherein said at least one form of said pharmaceutical compound has said basic salt in each said therapeutic dose, said basic salt having a concentration between about 1mM and about 1M per therapeutic dose.

12.(Canceled)

13.(Previously Amended) An acid-labile pharmaceutical compound as claimed in Claim 7, wherein said artificial feeding tube is at least one of nasogastric tube, nasoduodenal tube, nasojejunal tube, orogastric tube, oroduodenal tube, orojejunal tube, gastrostomy tube and jejunostomy tube.

14. (Original) An acid-labile pharmaceutical compound as claimed in Claim 13, wherein said gastrotomy tube and jejunostomy tube may be provided by at least one of surgical, radiological and endoscopical means.

15. (Canceled)

16. (Original) An acid-labile pharmaceutical compound as claimed in Claim 1, wherein said benzimidazole compound is one of omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole.